One study identified EYA2 as a potential target for molecular therapy in a subtype of acute myeloid leukemia (Ono et al., 2017), whereas OCSTAMP mRNA levels were connected to multiple myeloma (Wang et al., 2020) and TP53RK expression is inversely correlated with multiple myeloma survival (Hideshima et al., 2017). The gene discussed is EYA2; the disease is acute myeloid leukemia.